These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30639219)

  • 1. Albumin fusion improves the pharmacokinetics and in vivo antitumor efficacy of canine interferon gamma.
    Li B; Chen A; Zou S; Wu J; Wang H; Chen R; Luo M
    Int J Pharm; 2019 Mar; 558():404-412. PubMed ID: 30639219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and characterization of albumin fusion protein canine IFNγ-CSA in baculovirus-insect cell expression system.
    Li B; Wu J; Zou S; Zhai J; Chen A; Bu W; Chen R; Luo M
    Protein Expr Purif; 2019 Oct; 162():32-37. PubMed ID: 31100416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
    Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
    Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene delivery of albumin binding peptide-interferon-gamma fusion protein with improved pharmacokinetic properties and sustained biological activity.
    Miyakawa N; Nishikawa M; Takahashi Y; Ando M; Misaka M; Watanabe Y; Takakura Y
    J Pharm Sci; 2013 Sep; 102(9):3110-8. PubMed ID: 23463584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
    Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
    Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
    Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
    Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged circulation half-life of interferon γ activity by gene delivery of interferon γ-serum albumin fusion protein in mice.
    Miyakawa N; Nishikawa M; Takahashi Y; Ando M; Misaka M; Watanabe Y; Takakura Y
    J Pharm Sci; 2011 Jun; 100(6):2350-7. PubMed ID: 21246562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
    Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
    Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.
    Fam CM; Eisenberg SP; Carlson SJ; Chlipala EA; Cox GN; Rosendahl MS
    J Interferon Cytokine Res; 2014 Oct; 34(10):759-68. PubMed ID: 24841172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
    Sung C; Nardelli B; LaFleur DW; Blatter E; Corcoran M; Olsen HS; Birse CE; Pickeral OK; Zhang J; Shah D; Moody G; Gentz S; Beebe L; Moore PA
    J Interferon Cytokine Res; 2003 Jan; 23(1):25-36. PubMed ID: 12639296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
    Shen X; Wang L; Xu C; Yang J; Peng R; Hu X; Wang F; Zheng H; Lao X
    Int Immunopharmacol; 2019 Sep; 74():105662. PubMed ID: 31220695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of antiviral and anticellular activities of human recombinant interferon-gamma.
    Gomi K; Morimoto M; Nakamizo N
    Jpn J Cancer Res; 1985 Mar; 76(3):224-34. PubMed ID: 3922841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activities of human recombinant interferon-gamma against cervical tumor transplanted into nude mice.
    Iwasaka T; Tsugitomi H; Ohkuma Y; Yoshimura T; Sugimori H
    Acta Obstet Gynecol Scand; 1987; 66(6):501-5. PubMed ID: 3122516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of human recombinant interferon-gamma and -beta against human osteosarcoma transplanted into nude mice.
    Gomi K; Oka T; Morimoto M
    J Pharmacobiodyn; 1986 Nov; 9(11):879-88. PubMed ID: 3104572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats.
    Li F; Li QH; Wang JY; Zhan CY; Xie C; Lu WY
    J Control Release; 2012 Apr; 159(2):261-70. PubMed ID: 22226772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
    Chen JH; Zhang XG; Jiang YT; Yan LY; Tang L; Yin YW; Cheng DS; Chen J; Wang M
    Cancer Immunol Immunother; 2010 Sep; 59(9):1335-45. PubMed ID: 20473755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
    J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris.
    Lei J; Guan B; Li B; Duan Z; Chen Y; Li H; Jin J
    Protein Expr Purif; 2012 Jul; 84(1):154-60. PubMed ID: 22609631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.